Literature DB >> 27489518

Outcome of radiotherapy for pituitary adenomas.

Patricia Sebastian1, Rajesh Balakrishnan1, Bijesh Yadav2, Subhashini John1.   

Abstract

AIM: The aim of this study was to analyze the outcome and toxicities and its correlation to patient related and treatment related factors.
BACKGROUND: Pituitary adenomas are treated by radiation therapy (RT) as one of the modalities along with surgery and medical therapy. RT to pituitary adenomas is a challenge due to adjacent dose limiting structures such as optic apparatus and hypothalamus.
MATERIALS AND METHODS: Between January 2004 and December 2010, 94 patients treated for pituitary adenoma with RT who had hospital records of a minimum follow-up of 1 year were included in the analysis. Tests of correlation were done with regards to treatment factors.
RESULTS: Male preponderance was noted in our patient population. Nonfunctioning and functioning tumors were equal in number in this series. Hypopituitarism was associated in 58.5% of patients prior to RT. Radiological tumor progression was seen in one patient (1/94) who had a nonfunctioning tumor. Among functioning tumors, biochemical remission was seen in 93.6% of patients at a median follow-up of 6 years.
CONCLUSIONS: Visual complication was seen in 5.3% of patients and worsening or new onset hypopituitarism was seen in 6.4%. Conventional 3-field technique was associated with significantly more visual complication compared to Stereotactic Radiation Therapy (SRT) technique. Doses ≤50.4 Gy showed a trend of reduced rate of visual and endocrine complications with no compromise in efficacy.

Entities:  

Keywords:  3DCRT, 3 dimensional conformal radiotherapy; ACTH, adrenocorticotropic hormone; CR, complete response; CT, computerized tomography; Complications; FSH, follicle-stimulating hormone; FSRT, fractionated stereotactic radiotherapy; GH, growth hormone; GTC, Gill Thomas Cosman; Gy, Gray; Hypopituitarism; MRI, magnetic resonance imaging; MV, megavoltage; PR, partial response; Pituitary; RT, radiation therapy; Radiotherapy; SD, stable disease; SPSS, Statistical Package for the Social Sciences; SRS, stereotactic radiosurgery; SRT, stereotactic radiotherapy; Visual; cGy, centiGray

Year:  2016        PMID: 27489518      PMCID: PMC4950161          DOI: 10.1016/j.rpor.2016.06.002

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  20 in total

1.  A single centre's experience of stereotactic radiosurgery and radiotherapy for non-functioning pituitary adenomas with the Linear Accelerator (Linac).

Authors:  P J Wilson; K J De-Loyde; J R Williams; R I Smee
Journal:  J Clin Neurosci       Date:  2012-01-25       Impact factor: 1.961

2.  Neurocognitive changes in pituitary adenoma patients after fractionated external beam radiotherapy versus gamma knife radiosurgery.

Authors:  Judith Murovic; Steven Chang
Journal:  World Neurosurg       Date:  2011-12-17       Impact factor: 2.104

3.  Is it possible to avoid hypopituitarism after irradiation of pituitary adenomas by the Leksell gamma knife?

Authors:  Josef Marek; Jana Jezková; Václav Hána; Michal Krsek; L'ubomíra Bandúrová; Ladislav Pecen; Vilibald Vladyka; Roman Liscák
Journal:  Eur J Endocrinol       Date:  2010-11-11       Impact factor: 6.664

Review 4.  Comparative effectiveness review of treatment options for pituitary microadenomas in acromegaly.

Authors:  Nicholas F Marko; Emily LaSota; Amir H Hamrahian; Robert J Weil
Journal:  J Neurosurg       Date:  2012-06-22       Impact factor: 5.115

Review 5.  Role of stereotactic radiosurgery in the management of pituitary adenomas.

Authors:  Frederic Castinetti; Jean Régis; Henry Dufour; Thierry Brue
Journal:  Nat Rev Endocrinol       Date:  2010-02-23       Impact factor: 43.330

6.  The efficacy of conventional radiation therapy in the management of pituitary adenoma.

Authors:  R Sasaki; M Murakami; Y Okamoto; K Kono; E Yoden; T Nakajima; S Nabeshima; Y Kuroda
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-07-15       Impact factor: 7.038

7.  Long-term outcomes of radiotherapy for pituitary adenomas.

Authors:  Felicia E Snead; Robert J Amdur; Christopher G Morris; William M Mendenhall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-09       Impact factor: 7.038

8.  Radiotherapy for pituitary adenomas: long-term outcome and complications.

Authors:  Chai Hong Rim; Dae Sik Yang; Young Je Park; Won Sup Yoon; Jung Ae Lee; Chul Yong Kim
Journal:  Radiat Oncol J       Date:  2011-09-30

Review 9.  Pituitary adenoma: a radiotherapeutic perspective.

Authors:  Christopher S Platta; Christopher Mackay; James S Welsh
Journal:  Am J Clin Oncol       Date:  2010-08       Impact factor: 2.339

10.  Clonal origin of pituitary adenomas.

Authors:  V Herman; J Fagin; R Gonsky; K Kovacs; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  1990-12       Impact factor: 5.958

View more
  4 in total

1.  Outcome of partially irradiated recurrent nonfunctioning pituitary macroadenoma by gamma knife radiosurgery.

Authors:  Chiung-Chyi Shen; Weir-Chiang You; Ming-Hsi Sun; Shinh-Dung Lee; Hsi-Kai Tsou; Yen-Ju Chen; Meei-Ling Sheu; Jason Sheehan; Hung-Chuan Pan
Journal:  J Neurooncol       Date:  2018-06-13       Impact factor: 4.130

Review 2.  Management of nonfunctioning pituitary tumors: radiotherapy.

Authors:  Giuseppe Minniti; John Flickinger; Barbara Tolu; Sergio Paolini
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

3.  Radiomics Approach for Prediction of Recurrence in Non-Functioning Pituitary Macroadenomas.

Authors:  Yang Zhang; Ching-Chung Ko; Jeon-Hor Chen; Kai-Ting Chang; Tai-Yuan Chen; Sher-Wei Lim; Yu-Kun Tsui; Min-Ying Su
Journal:  Front Oncol       Date:  2020-12-18       Impact factor: 6.244

4.  Deep Learning for Prediction of Progression and Recurrence in Nonfunctioning Pituitary Macroadenomas: Combination of Clinical and MRI Features.

Authors:  Yan-Jen Chen; Hsun-Ping Hsieh; Kuo-Chuan Hung; Yun-Ju Shih; Sher-Wei Lim; Yu-Ting Kuo; Jeon-Hor Chen; Ching-Chung Ko
Journal:  Front Oncol       Date:  2022-04-20       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.